Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.

N.S. Stuart; M.B. McIllmurray; J.L. Bishop; S.R. Johnston; C.G. Price; S.M. O'Reilly; J.K. Joffe; F. Neave; E.C. Whipp

doi:10.1016/j.clon.2007.10.013

Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.

N.S. Stuart
, M.B. McIllmurray
, J.L. Bishop
, S.R. Johnston
, C.G. Price
, S.M. O'Reilly
, J.K. Joffe
, F. Neave
, E.C. Whipp

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	152-156
Journal	Clinical Oncology
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.clon.2007.10.013
Publication status	Published - 1 Mar 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

ONCOLOGY

Access to Document

10.1016/j.clon.2007.10.013

Cite this

@article{6d326bddea6444d3a72b8b13990704da,

title = "Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.",

keywords = "ONCOLOGY",

author = "N.S. Stuart and M.B. McIllmurray and J.L. Bishop and S.R. Johnston and C.G. Price and S.M. O'Reilly and J.K. Joffe and F. Neave and E.C. Whipp",

year = "2008",

month = mar,

day = "1",

doi = "10.1016/j.clon.2007.10.013",

language = "English",

volume = "20",

pages = "152--156",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.

AU - Stuart, N.S.

AU - McIllmurray, M.B.

AU - Bishop, J.L.

AU - Johnston, S.R.

AU - Price, C.G.

AU - O'Reilly, S.M.

AU - Joffe, J.K.

AU - Neave, F.

AU - Whipp, E.C.

PY - 2008/3/1

Y1 - 2008/3/1

KW - ONCOLOGY

U2 - 10.1016/j.clon.2007.10.013

DO - 10.1016/j.clon.2007.10.013

M3 - Article

SN - 0936-6555

VL - 20

SP - 152

EP - 156

JO - Clinical Oncology

JF - Clinical Oncology

IS - 2

ER -